Shannon Sirk, Ph.D.

We will isolate bacterial species that normally live in the respiratory tract, engineer them to produce targeted biological therapeutics, and reintroduce them into their native environment to colonize the mucosa and deliver virus-blocking biological drugs. This approach will establish an adaptable platform for cost-effective and rapid responses to future respiratory pathogenic threats.